This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

Effect of Tamsulosin on Stone Expulsion and Pain Resolution in ED Patients With Ureterolithiasis (Flowmax)

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
WellSpan Health
ClinicalTrials.gov Identifier:
NCT00762424
First received: September 26, 2008
Last updated: December 16, 2014
Last verified: December 2014
  Purpose
Tamsulosin (Flowmax)is approved by the FDA for the treatment for enlarged prostate. Several studies regarding the use of Tamsulosin for the treatment of lower kidney stones have been carried out in the non-Emergency Department setting. This study will compare Tamsulosin 0.4 mg with placebo in regards to rate and time of stone passing and will also look at amount of pain. The purpose of this study is to compare the usefulness of Tamsulosin versus placebo on time to stone passage and pain relief in Emergency Department patients with kidney stones.

Condition Intervention
Kidney Stone Drug: Flowmax Drug: placebo

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Care Provider)
Primary Purpose: Treatment
Official Title: Effect of Tamsulosin on Stone Expulsion and Pain Resolution in ED Patients With Ureterolithiasis

Resource links provided by NLM:


Further study details as provided by WellSpan Health:

Primary Outcome Measures:
  • Time of Stone Passage [ Time Frame: 10 Days ]
    Upon discharge, patient must be able to take the medication for 10 days and strain his/her urine. Patient must log the date and time of stone passage, if known.


Enrollment: 53
Study Start Date: June 2007
Study Completion Date: January 2011
Primary Completion Date: January 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: Tamsulosin Drug: Flowmax
0.4 mg once a day until stone passage total = 9 tablets
Placebo Comparator: Placebo Drug: placebo
cornstarch

  Eligibility

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • 18 y.o. or older
  • diagnosed with a kidney stone less than or equal to 10 mm determined by CT scan
  • physician has made the decision that you will be discharged to home
  • must be able to take study medication for up to 10 days and strain your urine
  • must be able to keep a record of pain medication taken and complete a pain scale rating

Exclusion Criteria:

  • patients currently taking: Tamsulosin (Flowmax), calcium channel blockers, beta blockers, alpha blockers, Sildenaphil (Viagara), Tadalaphil (Cilias), Warfarin (Coumadin, Jantoven), Cimetidine (Tagamet, Tagamet HB)
  • patients with a clinical and laboratory signs of: urinary tract infection, multiple kidney stones, diabetes, kidney failure, hypotension, pregnancy, fever
  • patient known to have hypersensitivity to Tamsulosin
  • patient history of cataract surgery
  • inability of patient to perform visual pain scale
  • allergy or intolerance to acetaminophen/oxycodone
  • patient is unable to understand informed consent
  • prisoners
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00762424

Locations
United States, Pennsylvania
York Hospital Emergency Department
York, Pennsylvania, United States, 17405
Sponsors and Collaborators
WellSpan Health
Investigators
Principal Investigator: Marc Pollack, MD, PhD WellSpan Health
  More Information

Responsible Party: WellSpan Health
ClinicalTrials.gov Identifier: NCT00762424     History of Changes
Other Study ID Numbers: 0607030
Study First Received: September 26, 2008
Results First Received: December 16, 2013
Last Updated: December 16, 2014

Keywords provided by WellSpan Health:
Kidney stone
Ureterolithiasis
Tamsulosin
Flowmax
Emergency Department

Additional relevant MeSH terms:
Calculi
Kidney Calculi
Nephrolithiasis
Ureterolithiasis
Ureteral Calculi
Pathological Conditions, Anatomical
Kidney Diseases
Urologic Diseases
Urolithiasis
Urinary Calculi
Ureteral Diseases
Tamsulosin
Adrenergic alpha-1 Receptor Antagonists
Adrenergic alpha-Antagonists
Adrenergic Antagonists
Adrenergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs
Urological Agents

ClinicalTrials.gov processed this record on September 25, 2017